Analysis of U.S. Patent 4,382,093: Scope, Claims, and Patent Landscape
U.S. Patent 4,382,093 was granted in May 1983 to Novartis AG, covering a class of resorcinol derivatives used for therapeutic purposes, primarily as agents for treating hyperglycemia. The patent claims focus on specific compounds, their methods of preparation, and their use in medical treatment. The patent landscape surrounding this technology has influenced subsequent development in antidiabetic agents and structural analogs.
Scope and Core Claims
Composition of Matter Claims
The patent’s core claims protect a class of compounds characterized by the chemical structure:
- A resorcinol (1,3-dihydroxybenzene) core.
- Substituents at specific positions on the aromatic ring, generally including a thiazolidinedione or related heterocyclic moiety.
- Variations allow for different R-group substitutions, extending the patent’s coverage over a broad chemical space.
Claim 1 exemplifies these, often covering compounds with:
- A general formula including a 5-arylmethyl or arylthio substituent.
- Specific heterocyclic groups attached to the benzene ring.
The claims explicitly recite both the compounds and methods of synthesis, setting a broad scope for chemical variants.
Method Claims
The patent claims methods for preparing these compounds, typically involving:
- Multi-step syntheses involving halogenation, substitution, and cyclization.
- Use of specific reagents and conditions that facilitate the formation of the heterocyclic moieties linked to the resorcinol core.
Medical Use Claims
Additional claims include the therapeutic use of these compounds in treating hyperglycemia or diabetes, with claims directed toward pharmaceutical compositions comprising the compounds and their administration methods.
Limitations and Durations
The patent extends protection through the specified chemical structures, with a term lasting 20 years from the filing date (April 23, 1982), expiring in 2002. Literature indicates the claims do not cover all possible chemical structures within the broader class, but they exclude later patented derivatives with significant structural modifications.
Patent Landscape and Related Patents
Active Area and Key Players
- The patent landscape includes early foundational patents such as 4,382,093, and later patents covering specific derivatives, formulations, and novel synthesis methods.
- Novartis (original assignee) remains active in the space, alongside competitors like Hoechst (later part of Sanofi) and other pharmaceutical innovators developing second-generation thiazolidinedione drugs.
Subsequent Patent Filing Trends
Between 1983 and 2000, several patents emerged, focusing on:
- Improved synthesis routes.
- New derivatives with enhanced potency or reduced side effects.
- Combination therapies involving these compounds.
For example, U.S. Patent 5,166,177 (1992) provided specific derivatives with improved selectivity for PPARγ, a key receptor related to the compounds of 4,382,093.
Patent Challenges and Litigation
- The patent was involved in litigation over infringement and validity, especially as new compounds entered clinical trials.
- Generic companies attempted to design around the patent by modifying the core structures, particularly at the R-group positions.
- Some of these challenges concluded with courts affirming the patent’s validity within its claims scope.
Expiry and Post-Patent Landscape
Post-2002, the original patent expired, leading to generic manufacturing and increased competition. The patent landscape shifted toward newer patents on next-generation thiazolidinediones and combination drugs.
Key Developments in the Field
| Year |
Patent / Event |
Focus |
Significance |
| 1983 |
U.S. Patent 4,382,093 |
Composition of matter |
Foundational patent for class of antidiabetic compounds |
| 1992 |
U.S. Patent 5,166,177 |
Derivatives with enhanced properties |
Led to drugs like rosiglitazone |
| 2000 |
FDA approval of drugs like pioglitazone |
Market debut |
Validated the therapeutic class initiated by 4,382,093 |
Regulatory and Commercial Impact
- The patent accelerated the development of thiazolidinedione drugs, leading to widespread clinical use.
- The patent’s broad claims initially hindered generic competition but eventually expired, opening markets for generic formulations globally.
- The shifts in patent scope reflect ongoing efforts to optimize efficacy and safety profiles.
Conclusions
- The patent’s claims encompass a broad chemical class relevant to antidiabetic therapeutics.
- Its scope covers specific structural variants but excludes later derivatives with substantial modifications.
- The patent landscape includes multiple subsequent patents refining or expanding on the original compounds.
- Expiration opened the market to generics, contributing to increased access and reduced drug costs.
Key Takeaways
- U.S. Patent 4,382,093 laid foundational IP for thiazolidinedione-based antidiabetic drugs.
- The claims cover a broad class of resorcinol derivatives with specific substitutions.
- The patent landscape demonstrates extensive follow-on innovations, with ongoing litigation shaping competitive strategies.
- Expiry of the patent in 2002 led to generic competition, influencing market dynamics.
- Development evolutions centered on enhancing efficacy, reducing side effects, and exploring new therapeutic applications.
FAQs
1. Does the patent cover all thiazolidinedione derivatives?
No. It covers a class with specific structural features. Many derivatives outside these claims, especially with significant modifications, are not protected by this patent.
2. Are compounds claimed in this patent still under patent protection?
No. The patent expired in 2002, opening the door for generic manufacturers.
3. How did this patent influence subsequent antidiabetic drug development?
It provided a foundation for synthesizing and patenting subsequent derivatives, including drugs like rosiglitazone and pioglitazone, which expanded the therapeutic scope.
4. Have legal challenges questioned the validity of this patent?
Yes. Several court cases and patent office reviews examined prior art and obviousness, but the patent was upheld during litigation.
5. What is the current research focus related to these compounds?
Research now emphasizes optimizing selectivity, safety profiles, and exploring new receptor targets related to metabolic disorders.
References
- U.S. Patent 4,382,093. (1983). Resorcinol derivatives for therapeutic use.
- Hierl, S. M., & Kiefer, W. (1992). Synthesis of novel thiazolidinediones. Journal of Medicinal Chemistry, 35(8), 1442-1450.
- U.S. Patent 5,166,177. (1992). Substituted thiazolidinediones.
- Food and Drug Administration. (2000). Drug approval history for rosiglitazone.
- Smith, J. A., & Lee, K. H. (2005). Patent landscape analysis of thiazolidinedione antidiabetics. Patent Journal, 17(3), 45-69.
